Drug Search Results
More Filters [+]

Spebrutinib

Alternative Names: spebrutinib, avl-292, cc-292
Latest Update: 2024-01-18
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Btk Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Spebrutinib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Arthritis, Rheumatoid

Phase 1: Healthy Volunteers|Lymphocytic Chronic B-Cell Leukemia|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Chronic Lymphoid Leukemia|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Waldenstrom Macroglobulinemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CC-122-DLBCL-001

P1

Terminated

Diffuse Large B-Cell Lymphoma|Follicular Lymphoma

2023-12-12

CC-292-CLL-001

P1

Completed

Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia

2019-01-23

47%

CC-292-RA-001

P2

Completed

Arthritis, Rheumatoid

2016-01-01

CC-292-CLL-002

P1

Completed

Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia

2015-12-01

Recent News Events